PRENATAL METHAMPHETAMINE EXPOSURE AND CHILD DEVELOPMENT (IDEAL)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We have established a Community Research Network (CRN), to conduct a longitudinal study or prenatal methamphetamine (MA) exposure and child outcome in four areas in which MA use is prevalent. The data collection sites include 9 hospitals with a combined annual delivery rate or approximately 27,300 newborn infants. Exposure status will be determined by maternal self-report and/or GC/MS confirmation of a positive meconium screen. We are projecting an average 4% prevalence rate of prenatal MA exposure across the sites. The sample will include 254 subjects in the MA exposed group and 254 subjects in the comparison group matched for other drug use, prematurity, social class, gender and race. This sample size provides sufficient power to detect small statistical effects with controls for appropriate covariates. Enrollment started 9/4/2002. Our plan is to conduct a three-year longitudinal study with 1 year to screen and recruit the sample and developmental follow-up in the newborn period, 1, 2, and 3 years and a home visit at 18 months. Measures of the child include domains of arousal regulation, cognition, social relationships, neuromotor, neuroendocrine function, and medical status. Measures of psychosocial risk factors include caregiving context and caregiver characteristics. We will test hypotheses related to the effects of prenatal MA exposure on the child outcome when covariates including other drug use are controlled and hypotheses related to the role of psychosocial risk factors mediating effects of prenatal MA exposure on child outcome. This study will enable us to bring to bear experiences and advances in methods and lessons learned from the study of prenatal exposure to other drugs to the study of prenatal MA exposure, as well as research and clinical expertise with MA.